Skip to main content
. Author manuscript; available in PMC: 2012 Feb 15.
Published in final edited form as: Cancer Res. 2011 Feb 8;71(4):1356–1361. doi: 10.1158/0008-5472.CAN-10-2852

Table 3.

Association between rs748404-T and lung cancer in 7 case control sample sets

Population OR CI95 P cases (N) cases
(F)		 cont.
(N)		 cont.(F) Phetc I2d
ICELAND a 1.20 1.08-1.33 0.00052 1,447 0.825 36,256 0.797
USA 1.19 0.89-1.59 0.246 186 0.796 838 0.766
NETHERLANDS 1.07 0.90-1.27 0.456 528 0.777 1,832 0.766
SPAIN 1.10 0.93-1.29 0.27 548 0.759 1,432 0.742
OVERALL b 1.15 1.07-1.24 0.00025 2,709 0.79 40,358 0.768 0.63 0
From Broderick et al. 1.15 1.09-1.20 1.08×10−6 7,560 8,205
All combined 1.15 1.10-1.20 1.1×10−9 10,269 48,563 0.78 0

Shown are the allelic odds-ratio (OR), 95% CI and P values based on the multiplicative model, the number of individuals (N) and the allelic frequency (F) of the variant in cases and controls. All P values are two-sided.

a

The Icelandic results are obtained by combining data from individuals genotyped directly or by familial imputation. Results for the Icelandic population were adjusted by the method of genomic control.

b

For the combined study populations, the reported control frequency was the average, unweighted control frequency of the individual populations, while the OR and the P value were estimated using the Mantel-Haenszel model.

c

Phet denotes the tests of heterogeneity performed by comparing the null hypothesis of the effect being the same in all populations to the alternative hypothesis of each population having a different effect using a likelihood ratio test.

d

I2 takes values between 0% and 100% and describes the proportion of the total variation in estimates that is due to heterogeneity.